Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro

Journal of Clinical Virology

Volumn 36, Issue 4, 2006, Pages 249-257

  Su, C ^a   Melby, T ^b   DeMasi, R ^b   Ravindran, P ^a   Heilek Snyder, G ^a  

^a ROCHE BIOSCIENCE   (United States)

^b Trimeris Inc   (United States)

Author keywords

Enfuvirtide; Fusion inhibitors; HIV; T 20; TORO

Indexed keywords

AMINO ACID; ENFUVIRTIDE; GLYCOPROTEIN E1; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VIRUS FUSION PROTEIN;

ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GEOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DOMAIN; STEP WISE MULTIPLE REGRESSION; VIROLOGY; VIRUS GENOME; VIRUS ISOLATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY;

EID: 33745993903     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.03.007     Document Type: Article

References (40)

1. Alam S.M., Paleos C.A., Liao H.X., Scearce R., Robinson J., et al. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res Hum Retroviruses 20 (2004) 836-845
2. Arastéh K., Lazzarin A., Clotet B., Lalezari J.P., Cooper D., et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. 15th International AIDS Conference. Bangkok, Thailand, 11-16 July (2004) [Abstract MoOrB1058]
3. Beerenwinkel N., Sing T., Lengauer T., Rahnenfuehrer J., Roomp K., et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21 (2005) 3943-3950
4. Baldwin C.E., Sanders R.W., Deng Y., Jurriaans S., Lange J.M., et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 78 (2004) 12428-12437
5. Cao J., Bergeron L., Helseth E., Thali M., Repke H., et al. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 67 (1993) 2747-2755
6. Cosson P. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J 15 (1996) 5783-5788
7. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74 (2000) 8358-8367
8. Derdeyn C.A., Decker J.M., Sfakianos J.N., Zhang Z., O'Brien W.A., et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 75 (2001) 8605-8614
9. Furuta R.A., Wild C.T., Weng Y., and Weiss C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5 (1998) 276-279
10. Greenberg M., Melby T., Sista P., DeMasi R., Cammack N., et al. Baseline (BL) and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 10-14 February (2003) [Abstract 141]
11. Greenberg M.L., and Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54 (2004) 333-340
12. Greenberg M.L., McDanal C.B., Stanfield-Oakley S.A., Jin L., Tremblay C., et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 4-8 February (2001) [Abstract 473]
13. Heil M.L., Decker J.M., Sfakianos J.N., Shaw G.M., Hunter E., et al. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 78 (2004) 7582-7589
14. Kalia V., Sarkar S., Gupta P., and Montelaro R.C. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation. J Virol 77 (2003) 3634-3646
15. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
16. LaBranche C.C., Hoffman T.L., Romano J., Haggarty B.S., Edwards T.G., et al. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 73 (1999) 10310-10319
17. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 (2003) 2175-2185
18. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348 (2003) 2186-2195
19. Liu S., Lu H., Niu J., Xu Y., Wu S., et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280 (2005) 11259-11273
20. Lu J., Sista P., Giguel F., Greenberg M., and Kuritzkes D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 78 (2004) 4628-4637
21. Melby T., DeMasi R., Kuritzkes D., Heilek-Snyder G., Salgo M., et al. Analysis of virological response and enfuvirtide resistance through 48 weeks in the TORO 1 and 2 studies. XIII International HIV Drug Resistance Workshop. Tenerife, Spain, 8-12 June (2004) [Abstract 165]
22. Melby T., DeMasi R., Miralles G., Heilek-Snyder G., and Greenberg M. Evolution of enfuvirtide resistance in longitudinal samples obtained after continued enfuvirtide dosing post-virological failure. In program and abstracts of the XIV International Drug Resistance Workshop. Quebec City, Que., Canada, June 7-11 (2005) [Abstract 67]
23. Menzo S., Castagna A., Monachetti A., Hasson H., Danise A., et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 48 (2004) 3253-3259
24. Mink M., Janumpalli S., Davison D., Mosier S., Erickson J.B., et al. Correlation of gp41 binding and antiviral potencies of the T-20 fusion inhibitor using clinical trial isolate-derived sequences. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 4-8 February (2001) [Abstract 474]
25. Nameki D., Kodama E., Ikeuchi M., Mabuchi N., Otaka A., et al. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 79 (2005) 764-770
26. Platt E.J., Shea D.M., Rose P.P., and Kabat D. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J Virol 79 (2005) 4357-4368
27. Poveda E., Rodes B., Labernardiere J.L., Benito J.M., Toro C., et al. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74 (2004) 21-28
28. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 99 (2002) 16249-16254
29. Reeves J.D., Lee F.H., Miamidian J.L., Jabara C.B., Juntilla M.M., et al. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79 (2005) 4991-4999
30. Rimsky L.T., Shugars D.C., and Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72 (1998) 986-993
31. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280 (1998) 1949-1953
32. Roman F., Gonzalez D., Lambert C., Deroo S., Fischer A., et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33 (2003) 134-139
33. Sista P.R., Melby T., Davison D., Jin L., Mosier S., et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18 (2004) 1787-1794
34. Stanfield-Oakley S.A., Jeffrey J., McDanal C.B., et al. Determinants of susceptibility to enfuvirtide (ENF) map to gp41 in ENF-naive HIV-1. Antiviral Ther 8 (2003) S25 [Abstract]
35. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46 (2002) 1896-1905
36. Wyma D.J., Jiang J., Shi J., Zhou J., Lineberger J.E., et al. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 78 (2004) 3429-3435
37. Xu L., Hue S., Taylor S., Ratcliffe D., Workman J.A., et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 16 (2002) 1684-1686
38. Xu L., Pozniak A., Wildfire A., Stanfield-Oakley S.A., Mosier S.M., et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 49 (2005) 1113-1119
39. Yuan W., Craig S., Si Z., Farzan M., and Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 78 (2004) 5448-5457
40. Zollner B., Feucht H.H., Schroter M., Schafer P., Plettenberg A., et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 15 (2001) 935-936